When was Akava Therapeutics founded?

Akava Therapeutics was founded in 2019 and raised its 1st funding round 6 years after it was founded.

Where is Akava Therapeutics located?

Akava Therapeutics is headquartered in Evanston, United States.

Is Akava Therapeutics a funded company?

Akava Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Feb 05, 2025.

When was the latest funding round of Akava Therapeutics?

Akava Therapeutics' latest funding was a $***** Seed round on Feb 05, 2025, with participation from 0 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $2.08B in funding in 2026 to date.

Where does Akava Therapeutics rank among its competitors?

Akava Therapeutics ranks 2583rd amongst 3619 active competitors, of which 1244 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Akava Therapeutics, which secured $100K in Feb, 2025.

Who are the top competitors of Akava Therapeutics?

Akava Therapeutics' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Among them, Akava Therapeutics secured the most recent funding round in February, 2025.

Akava Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Akava Therapeutics is a seed company based in Evanston (United States), founded in 2019 by Richard B Silverman. It operates as a Developer of small molecule therapeutics for neurodegenerative diseases and cancer. Akava Therapeutics has raised $100K in funding. The company has 3619 active competitors, including 1244 funded and 859 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics.

Company Details

Developer of small molecule therapeutics for neurodegenerative diseases and cancer. It offers a lead compound, AKV9 a protein aggregation inhibitor that improve the health of upper motor neurons that degenerate in motor neuron diseases. It also offers Ornithine Aminotransferase Inactivators for hepatocellular carcinoma, Neuronal Nitric Oxide Synthase Inhibitors for melanoma, and others.

Key Metrics

Founded Year

2019

Location

Evanston, United States

Stage

Seed

Total Funding

$100K in 1 round

Latest Funding Round

Seed, Feb 05, 2025, $*****

Ranked

2583^rd among 3619 active competitors

Similar Companies

Jazz Pharmaceuticals & 3462 more

View Akava Therapeutics' full profile

Akava Therapeutics has raised a total funding of $100K over 1 round.

Here is the list of recent funding rounds of Akava Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 05, 2025	9326350	Seed	2117678	8448699	8361344	4755884

Access funding benchmarks and valuations. Sign up today!

View details of Akava Therapeutics's funding rounds and investors

The founders of Akava Therapeutics is Richard B Silverman.

Here are the details of Akava Therapeutics' key team members:

Richard B Silverman: Founder of Akava Therapeutics.

View details of Akava Therapeutics's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Akava Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Here is the list of Top 10 competitors of Akava Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
3rd	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
5th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
6th	Pacira 2006, Parsippany Troy Hills (United States), Public	Developer of injectable non-opioid products for post-surgical pain control	$85M	HBM Healthcare Investments, Orbimed & 6 others	72/100
7th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
8th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
9th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	Kaccelerator, BB Biotech & 7 others	71/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	71/100
2583rd	Akava Therapeutics 2019, Evanston (United States), Seed	Developer of small molecule therapeutics for neurodegenerative diseases and cancer	$100K	-	25/100